DOSE ESCALATION OF ORAL RIBAVIRIN & INTRON A FOR FAILED-IFN HEPATITIS C

口服利巴韦林的剂量递增

• 批准号: 6118139
• 负责人: John G. McHutchison
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118139
• 关键词: clinical research; combination chemotherapy; dosage; drug screening /evaluation; hepatitis C; human subject; human therapy evaluation; immunotherapy; interferon alpha; liver disorder chemotherapy; ribavirin

This investigator-initiated study addresses the efficacy and safety of interferon alpha-2b and ribavirin in dose escalations of 400mg, 800mg, and 1000mg. THe biochemical and virological responses to treatment are measured at two time points: end of treatment response and six months posttreatment sustained response.

这项研究者发起的研究探讨了干扰素 α-2b 和利巴韦林在剂量递增至 400mg、800mg 和 1000mg 时的有效性和安全性。 在两个时间点测量对治疗的生化和病毒学反应：治疗反应结束和治疗后六个月持续反应。